KYMR Kymera Therapeutics, Inc.: institutional ownership and insider trading
302 funds reported holding $11.7B of Kymera Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $143M, with 50 new positions and 26 funds selling out; over the last 12 months insiders bought $172M and sold $415M on the open market.
Famous investors holding KYMR
- Two Sigma (Two Sigma Investments): $42.6M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $20.1M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $321K, 0.0% of the portfolio
Largest institutional holders of KYMR
- FMR LLC — $1.42B
- BAKER BROS. ADVISORS LP — $993M
- Avoro Capital Advisors LLC — $857M
- PRICE T ROWE ASSOCIATES INC /MD/ — $816M
- T. Rowe Price Investment Management, Inc. — $718M
- BlackRock, Inc. (BLK) — $635M
- VANGUARD GROUP INC — $488M
- BVF INC/IL — $444M
- WELLINGTON MANAGEMENT GROUP LLP — $421M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $343M
Recent KYMR insider trades
- Oct 1, 2026: Mainolfi Nello sold 30,000 shares ($3.41M)
- Sep 4, 2026: Adams Brian sold 6,371 shares ($744K)
- Jul 7, 2026: Mainolfi Nello sold 50,000 shares ($5.95M)
- Jul 1, 2026: Mainolfi Nello sold 80,000 shares ($9.22M)
5%+ owners
- FMR LLC: 14.3% (Schedule 13G/A, filed May 6, 2026)
- T. Rowe Price Associates, Inc.: 10.7% (Schedule 13G/A, filed Sep 8, 2026)
- T. Rowe Price Investment Management, Inc.: 6.7% (Schedule 13G, filed May 15, 2026)
- BVF PARTNERS L P/IL: 6.3% (Schedule 13D/A, filed Jun 26, 2026)